Expert Looks Forward to Potentially Practice-Changing Presentations at ASCO 2021

In preparation for the 2021 American Society of Clinical Oncology Annual Meeting, CancerNetwork® spoke with Alison Schram, MD, an assistant attending physician at Memorial Sloan Kettering Cancer Center, to discuss which abstracts she is excited to see presented at the meeting.

She highlighted impending results from the phase 3 RELATIVITY-047 trial (NCT03470922) of frontline relatlimab plus nivolumab (Opdivo) versus nivolumab alone in patients with advanced melanoma.1 She also looks forward to data from a late breaking abstract featuring results of the phase 3 OUTBACK trial (NCT01414608) examining adjuvant chemotherapy after chemoradiation for patients with locally advanced cervical cancer.2

Transcript:

The phase 3 RELATIVITY[-047] study, a trial in melanoma, is particularly exciting. As a [gynecologic] medical oncologist, I am interested in the cervical cancer study looking at OUTBACK chemotherapy, which I do think is practice changing. Many of us already do this and really are awaiting these results.

References

1. Lipson EJ, Tawabi HA, Schadendorf D, et al. Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047). J Clin Oncol. 2021;39(suppl 15):9503. doi:10.1200/JCO.2021.39.15_suppl.9503

2. Mileshkin LR, Moore KN, Barnes E, et al. Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase III OUTBACK Trial. J Clin Oncol. 2021;39(suppl 15):LBA3. doi:10.1200/JCO.2021.39.15_suppl.LBA3